Accepting Cases

Testosterone Lawsuits

About 6,000 cases pending in the testosterone multidistrict litigation allege use of testosterone products led to blood clots, heart attack, stroke and sudden death. So far, two trials over AbbVie Inc.’s AndroGel have ended in multimillion-dollar jury verdicts against the company.

Side effects related to testosterone therapy?

If you took a prescription testosterone product and suffered cardiac side effects or stroke, you may be eligible for compensation.

Testosterone Lawsuit Facts
  1. Number of Lawsuits More than 25,000
  2. Plaintiff Injuries Mini-stroke, stroke, heart attack and blood clotting
  3. Defendants AbbVie Inc.; Abbott Laboratories Inc.; Pharmacia & Upjohn Inc.; Pfizer Inc.; Auxilium Pharmaceuticals Inc.; Endo Pharmaceuticals Inc.; Eli Lilly & Co. and Actavis Inc.
  4. Bellwether Trial Dates June 5, 2017; July 17, 2017; Aug. 28, 2017; Oct. 9, 2017; Nov. 20, 2017; Jan. 8, 2018; May 15, 2018; and June 14, 2018
Legally Reviewed

Drugwatch content is legally reviewed for accuracy and quality.

Examples of trusted legal reviewers include qualified mass torts lawyers and certified paralegals.

Drugwatch writers gather lawsuit information by studying court records, watching lawsuit proceedings and speaking with experienced attorneys.

Testosterone lawsuits claim men who used testosterone replacement therapy suffered from heart attack, stroke, blood clots and sudden death.

The lawsuits, which involve the makers of popular products such as AndroGel and Depo-Testosterone, have been consolidated into a multidistrict litigation, a legal process courts use to manage many similar cases.

To date, more than 25,000 lawsuits have been filed against AbbVie, Eli Lilly & Co., Pfizer Inc., Endo International and other testosterone-product manufacturers. Seven cases have gone to trial.

Juries ordered AbbVie to pay $150 million and $140 million to two men who used AndroGel and suffered heart attacks. AbbVie trials ended in favor of the drugmaker in January and May 2018. Another jury ruled in favor of Endo International’s Auxilium unit. In December 2017, an Illinois federal judge threw out the $150 million verdict. A second trial in that case resulted in a $3.2 million verdict.

Four juries have ruled in favor of AbbVie. The most recent case was won by AbbVie on June 14, 2018. Another jury ruled in favor of Endo.

Jury verdicts could affect settlement negotiations going forward for the more than 6,000 remaining cases. So far, Eli Lilly, Endo International, Auxilium Pharmaceuticals and GlaxoSmithKline have reached tentative global settlements involving hundreds of cases. Endo announced on June 12, 2018, that it had set aside $200 million to settle 1,300 cases involving its testosterone product, Testim.

Attorneys continue to accept new cases on behalf of men who used testosterone products and then experienced heart attacks, strokes or blood clots called pulmonary embolism and deep vein thrombosis.

Surviving spouses or relatives may also be eligible for compensation if their loved ones’ use of testosterone products led to sudden death.

Status of Testosterone Lawsuits

Testosterone litigation is ongoing, meaning men who believe they suffered heart attack, stroke, pulmonary embolism or deep vein thrombosis as a result of using testosterone products, such as AndroGel, can still sue the products’ manufacturers.

The litigation is in the bellwether trial phase. This means a few representative cases are going to trial first. The outcome of these cases could decide the fate of 6,000-plus lawsuits still pending.

These trials are scheduled to continue into 2019.

10 Things You Need to Know About Testosterone Lawsuits
  1. In March 2014, attorneys filed a motion to consolidate all federal testosterone lawsuits, including AndroGel lawsuits, in federal court in Illinois
  2. In June 2014, the U.S. Judicial Panel on Multidistrict Litigation ordered that 45 actions pending in four districts be consolidated and moved to the Northern District of Illinois under U.S. District Judge Matthew F. Kennelly
  3. At its peak, MDL-2545 IN RE: Testosterone Replacement Therapy Products Liability Litigation included more than 25,000 lawsuits
  4. In May 2018, the testosterone MDL had the sixth most pending lawsuits out of the 221 MDLs that were ongoing in U.S. federal courts
  5. The MDL is in the bellwether trial phase, which means the court has selected a few cases to go to trial so both sides can test their arguments with the goal of resolving the remaining cases
  6. Six AndroGel cases have gone to trial so far. One case initially resulted in a mistrial. Two trials ended in $140 million and $150 million jury verdicts against AbbVie Inc., though a federal judge threw out the $150 million verdict in December 2017. Jurors in a March 2018 retrial handed up a $3.2 million verdict. Four juries ruled in favor of AbbVie.
  7. Jurors in one federal case involving the drug Testim ruled in favor of the manufacturer, Endo International’s Auxilium, and declined to award damages
  8. A bellwether trial involving the drugmaker Activis is scheduled to start Aug. 6, 2018.
  9. Eli Lilly and Co. reached a global settlement in hundreds of federal lawsuits over Axiron. Endo International agreed to settle 1,300 Testim lawsuits for $200 million. Endo’s subsidiary Auxilium Pharmaceuticals manufactures Testim. GlaxoSmithKline co-promotes Testim.
  10. Men and their families can still sue testosterone manufacturers for injuries including heart attack, stroke, deep vein thrombosis, pulmonary embolism and sudden death
Complications from Testosterone Replacement Therapy? Get a Free Case Review

Testosterone Multidistrict Litigation

The U.S. Judicial Panel on Multidistrict Litigation created the testosterone multidistrict litigation, or MDL, in June 2014 as a way of streamlining the pretrial proceedings for many similar lawsuits against makers of testosterone products.

The panel ordered that 45 lawsuits pending in four districts be consolidated and moved to the Northern District of Illinois. U.S. District Judge Matthew F. Kennelly is overseeing the MDL, formally called MDL-2545 IN RE: Testosterone Replacement Therapy Products Liability Litigation.

In issuing its order, the panel stated:
“All actions involve plaintiffs (or their survivors) who used one or more testosterone replacement therapies and contend that their (or their decedent’s) use of the drugs caused their injuries, which include heart attack, stroke, deep vein thrombosis, and pulmonary embolism.”

The number of lawsuits in the MDL reached more than 25,000, according to the U.S. District Court Northern District of Illinois website. As of May 2018, a total of 6,061 remained pending.

Of the 221 MDLs across the U.S., the testosterone MDL is especially complicated, with the sixth most pending actions, according to the U.S. Judicial Panel on Multidistrict Litigation’s May 2018 MDL statistics report.

Testosterone MDL Timeline
  • January 2014
    The FDA announced it was “investigating the risk of stroke, heart attack and death in men taking FDA-approved testosterone products.”
  • February 2014
    Five men sued Abbott Laboratories and its spinoff, AbbVie, Inc., alleging injuries caused by AndroGel.
  • March 2014
    The multidistrict litigation panel received a motion to consolidate all federal testosterone lawsuits, including the AndroGel lawsuits, in federal court in Illinois.
  • June 2014
    The panel ordered 45 actions pending in four districts be consolidated and moved to the Northern District of Illinois.
  • August 2014
    The court appointed attorneys to serve in leadership roles in the multidistrict litigation.
  • September 2015
    The court designated attorneys who will serve in leadership roles throughout the rest of the litigation.
  • August 2016
    U.S. Judge Matthew F. Kennelly selected AbbVie cases for bellwether trials.
  • March 2017
    The court appointed a settlement master to meet with both sides on a monthly basis to discuss settlement.
  • June 2017
    The first AbbVie bellwether trial ended in a mistrial after an attorney was hospitalized for a heart problem.
  • July 2017
    The second AbbVie bellwether trial ended in a $150 million jury verdict against AbbVie.
  • August 2017
    Federal jurors ruled for AbbVie in an AndroGel case.
  • October 2017
    A jury ordered AbbVie to pay $140 million to a man who used AndroGel and suffered a heart attack.
  • November 2017
    A jury in another bellwether trial ruled in favor of Endo and its Auxilium unit, declining to award damages to Steve Holtsclaw of Tennessee, who claimed he suffered a heart attack after taking the drug Testim.
  • December 2017
    An Illinois judge threw out a $150 million verdict against AbbVie. Eli Lilly reached tentative settlements in more than 500 cases.
  • January 2018
    An AndroGel bellwether trial ended with a verdict in favor of AbbVie.
  • February 2018
    The judge scheduled another trial in the AndroGel case in which he overturned the $150 million verdict.
  • March 2018
    Jurors in the retrial of Jesse Mitchell’s case handed up a $3.2 million verdict in his favor.
  • May 2018
    AbbVie won its third victory in the fifth federal bellwether trial involving AndroGel.
  • June 2018
    Endo International agreed to pay $200 million to settle about 1,300 Testim lawsuits. The sixth federal bellwether ended in AbbVie's fourth win.

Injuries You Can Sue For: Heart Attack, Stroke, Blood Clots & Death

Men who used testosterone products as prescribed by a doctor and suffered heart attack, stroke, pulmonary embolism or deep vein thrombosis may be eligible for compensation through a lawsuit. Relatives of men who died suddenly after using these products may also be eligible.

Injuries you can sue for include:
Heart attack
Testosterone products are linked to an increased risk of heart attack. If you experienced a heart attack within 90 days of using testosterone replacement therapy and before January 2014, you may have a claim.
Stroke
Men who used testosterone gels were 30 percent more likely to suffer from a stroke, also called a cerebrovascular accident or CVA. If you experienced a stroke within 90 days of using testosterone replacement therapy and before January 2014, you may have a claim.
Pulmonary embolism
Blood clots caused by testosterone therapy can block arteries in the lungs. If you experienced a pulmonary embolism within 90 days of using testosterone replacement therapy and before June 2014, you may have a claim.
Sudden death
Lawsuits say there is casual relationship between use of testosterone products and sudden cardiac death
Deep vein thrombosis
Dangerous blood clots that can travel to deep veins in the legs can develop as quickly as one month after starting testosterone treatment. If you developed deep vein thrombosis (DVT) within 90 days of using testosterone replacement therapy, you may have a claim.

Testosterone Lawsuit Allegations

Thousands of testosterone lawsuits filed in federal court all make the same allegation: Manufacturers of testosterone products put healthy men in danger by marketing the hormone to treat sexual dysfunction, age-related fatigue and other symptoms that go beyond the use approved by the U.S. Food & Drug Administration.

Testosterone replacement therapies were approved for use in the treatment of a medical condition known as hypogonadism, but drugmakers widely marketed the products for off-label use for a condition they allegedly invented and call “Low T.”

Lawsuits accuse makers of testosterone products of marketing the products as safe and effective for this off-label use, when in fact, the products reportedly provide little or no benefit for men without hypogonadism and the drugs can cause heart attack, stroke, blood clots and sudden death — serious medical problems for which the companies allegedly failed to provide adequate warnings.

Lawsuits accuse testosterone companies of:
  • Misrepresenting testosterone products as a safe and effective treatment for hypogonadism — the drastic decline in hormone levels caused by injury or disease — despite causing serious side effects
  • Exaggerating the benefits of their products and understating, omitting and/or failing to adequately warn patients and physicians about the risks and the monitoring required to ensure patient safety
  • Using “aggressive, award-winning direct-to-consumer and physician” marketing tactics to convince men to discuss testosterone therapy with their doctors
  • Engaging in “disease mongering” to increase sales instead of adequately warning consumers about the risks

Brands Named in Lawsuits: AndroGel, Depo-Testosterone & Fortesta

AndroGel is the testosterone product most often named in lawsuits. AbbVie Inc. manufactures AndroGel. AbbVie’s parent company, Abbott Laboratories, bought AndroGel from Solvay in 2010 and is also named in lawsuits.

Other brands named in lawsuits include Pfizer’s Depo-Testosterone, Eli Lilly & Co.’s Axiron, Endo Pharmaceutical’s Foresta and Auxilium Pharmaceuticals Inc.’s Testim. Actavis Inc. also faces lawsuits over its testosterone gel, Androderm.

Men who suffered heart suffered heart attack, stroke, pulmonary embolism or deep vein thrombosis may be eligible for compensation if they used any of the following testosterone products:

Brand Manufacturer
AndroGel AbbVie Inc.; Abbott Laboratories Inc.; AbbVie Products; Unimed; Solvay; Besins Inc.; Besins S.A.
Depo-Testosterone Pfizer Inc.; Pharmacia & Upjohn Inc.
Foresta Endo Pharmaceuticals
Delatestryl Endo Pharmaceuticals
Testim Auxilium Pharmaceuticals Inc.; GlaxoSmithKline; Endo Pharmaceuticals
Testopel Auxilium Pharmaceuticals Inc.; Endo Pharmaceuticals
Striant Auxilium Pharmaceuticals Inc.; Endo Pharmaceuticals
Androderm Actavis Inc., Actavis Pharma Inc., ALU, and Anda, Inc.

AndroGel Lawsuit

AndroGel is the most widely used type of testosterone replacement therapy. The drug brought in $1.15 billion in sales in 2012 alone. Sales in 2016 were $675 million.

AndroGel lawsuits say manufacturers Abbott and AbbVie “deceived potential users by relaying positive information through the press, including testimonials from retired professional athletes” and statistics suggesting a widespread need for the drugs “while downplaying known adverse and serious health risks,” Bloomberg reported.

One of the men who sued AbbVie was then-54-year-old Michael Gallagher of Virginia. He suffered myocardial infarction, congestive heart failure and other injuries after being prescribed the gel. He had no history of cardiac problems before taking the prescription drug. Gallagher claims he started AndroGel therapy after the defendants’ advertisements led him to attribute symptoms to low testosterone.

Depo-Testosterone Lawsuit

Several manufacturers of testosterone drugs are facing lawsuits in court filed by men who suffered heart attacks, blood clots and strokes. Pfizer and Pharmacia & Upjohn Co. are no exception.

In September 2014, Alvaro Roman Gutierrez took his case to court after using Depo-Testosterone and suffering heart problems he blames on the drug. He accuses Pfizer of “disease mongering” by downplaying the risks of the drug and exaggerating its benefits.

“As a direct and proximate result of the plaintiff’s use of Depo-Testosterone, also known as Testosterone Cypionate, and plaintiff’s reliance on defendants’ representations regarding the character and quality of the products and defendants’ failure to comply with federal requirements, plaintiff suffered serious physical injury, harm, damages and economic loss and will continue to suffer such harm, damages and economic loss in the future,” Gutierrez says in his complaint.

The complaint also says the drugmaker had a duty to warn the public and did not. Pfizer denies any wrongdoing and stands by its drug.

“We do not believe that the cases against Pfizer have merit, and we intend to defend these cases vigorously in court”

Pfizer spokesman Steven Danehy said in a statement

Pfizer is accustomed to fighting hormone drug lawsuits. In 2012, it paid $896 million to women who said their breast cancer was caused by the drug. Some doctors warn that testosterone might follow the same path as estrogen therapy.

In 2015, Judge Kennelly dismissed more than 1,000 lawsuits involving Depo-T. A federal appeals court upheld that ruling in February 2018.

Bellwether Trials and Testosterone Verdicts

AbbVie Inc. was the first testosterone manufacturer on trial. Judge Kennelly, the Illinois federal judge overseeing the MDL, identified about a half-dozen AbbVie cases for bellwether trials, which are test cases intended to try a widely contested issue.

The first four cases in the bellwether trials involve plaintiff claims that AndroGel caused myocardial infraction (heart attack) or stroke. The second group is made up of cases that allege blood clot injury, including pulmonary embolism and deep vein thrombosis.

Six cases over AbbVie Inc.’s AndroGel have been decided:
  • In June 2017, jurors began to hear the case of Jeffrey Konrad, a Tennessee man who says he suffered a heart attack after using AndroGel. However, the trial ended in a mistrial after an attorney was hospitalized for a heart problem. Konrad did eventually get a full trial in September. A jury awarded him $140 million.
  • In July 2017 a second bellwether case went to trial. Attorneys for Jesse Mitchell told the jury that the Oregon man suffered a heart attack at age 43, four years after he started using AndroGel. Jurors deliberated for about four days. They concluded AbbVie’s negligence was not the cause of Mitchell’s heart attack. Still, the jury found the company liable for false marketing, or fraudulent misrepresentation, and ordered AbbVie to pay Mitchell $150 million. Kennelly later overturned that verdict. A second trial in March 2018, ended in a verdict of $3.2 million for Mitchell.
  • A jury sided with AbbVie in August 2017. Three more juries sided with AbbVie in 2018 against men who blamed AndroGel for blood clots in their lungs – one in January involving plaintiff Robert Nolte, another in May against Arthur Myers and one in June against Robert Rowley.

Androgel Bellwether Cases:

JEFFREY KONRAD V. ABBVIE INC.
  • PLAINTIFFS: Jeffrey and Jana Konrad
  • ALLEGED INJURY: Heart attack
  • DATE OF ALLEGED INJURY: July 9, 2010
  • DATES OF ALLEGED ANDROGEL USE: May 2010 – June 2010
  • AGE AT INJURY: 49
  • AGE AT FIRST PRESCRIPTION: 49
  • TRIAL STATUS: Jury ordered AbbVie to pay Konrad $140 million
JESSE MITCHELL V. ABBVIE
  • PLAINTIFF: Jesse Mitchell
  • ALLEGED INJURY: Heart attack
  • DATE OF ALLEGED INJURY: November 18, 2012
  • DATES OF ALLEGED ANDROGEL USE: December 2007 – November 2012
  • AGE AT INJURY: 49
  • AGE AT FIRST PRESCRIPTION: 44
  • TRIAL STATUS: First trial ended in a mistrial; later a jury ordered AbbVie to pay Mitchell $150 million; a judge overturned the verdict in December 2017. In March 2018, jurors handed up a $3.2 million verdict.
ARTHUR MYERS V. ABBVIE
  • PLAINTIFF: Arthur Myers
  • ALLEGED INJURY: Pulmonary embolism
  • DATE OF ALLEGED INJURY: February 7, 2008
  • DATES OF ALLEGED ANDROGEL USE: June 2003 – August 2008
  • AGE AT INJURY: 42
  • AGE AT FIRST PRESCRIPTION: 37
  • TRIAL STATUS: Jurors ruled for AbbVie in May 2018
Robert Nolte v. AbbVie
  • PLAINTIFF: Robert Nolte
  • ALLEGED INJURY: Pulmonary embolism
  • DATE OF ALLEGED INJURY: November 1, 2012
  • DATES OF ALLEGED ANDROGEL USE: August 2012 – December 2012
  • AGE AT INJURY: 72
  • AGE AT FIRST PRESCRIPTION: 72
  • TRIAL STATUS: Jurors ruled for AbbVie
ROBERT ROWLEY V. ABBVIE
  • PLAINTIFF: Robert Rowley
  • ALLEGED INJURY: Deep vein thrombosis
  • DATE OF ALLEGED INJURY: April 27, 2013
  • DATES OF ALLEGED ANDROGEL USE: April 2012 – April 2013
  • AGE AT INJURY: 67
  • AGE AT FIRST PRESCRIPTION: 66
  • TRIAL STATUS: Jurors ruled for AbbVie
EDWARD CRIBBS V. ABBVIE
  • PLAINTIFF: Edward Cribbs
  • ALLEGED INJURY: Heart attack
  • DATE OF ALLEGED INJURY: May 25, 2012
  • DATES OF ALLEGED ANDROGEL USE: March 2010 – April 2014
  • AGE AT INJURY: 61
  • AGE AT FIRST PRESCRIPTION: 59
CECILE FROST V. ABBVIE
  • PLAINTIFF: Cecile Frost
  • ALLEGED INJURY: Stroke
  • DATE OF ALLEGED INJURY: February 21, 2013
  • DATES OF ALLEGED ANDROGEL USE: January 2012 – February 2013
  • AGE AT INJURY: 59
  • AGE AT FIRST PRESCRIPTION: 58

Testosterone Lawsuit Settlements

In December 2017, Eli Lilly and Co. settled about 400 cases that were part of the federal MDL. Details of the tentative settlement were not immediately disclosed. The cases involved people who claimed they were injured by the drug Axiron.

Also, in January 2018, Endo’s Auxilium Pharmaceuticals settled a lawsuit filed in state court in Philadelphia by a man who said his stroke was caused by the drug Testim. The parties didn’t release details of that resolution either.

In June 2018, Endo International announced it would pay $200 million to settle 1,300 Testim lawsuits. This included about 900 cases in the MDL.

Judge Kennelly had appointed Randi Ellis as the MDL’s settlement master in March 2017. Kennelly ordered Ellis to meet with both sides to discuss settlement. Ellis is an attorney who is frequently called upon to facilitate settlements.

Testosterone Class Action Status

The attention surrounding testosterone lawsuits is on the federal multidistrict litigation in Illinois.

All federal testosterone lawsuits have been consolidated and transferred to the MDL as a way of conserving time and resources.

Although testosterone class actions are not in the forefront right now, an MDL can lead to a class action.

FDA Actions and Testosterone Studies

Several studies have assessed the safety of testosterone products and found increased risk of heart attack, stroke and blood clots. As a result, the FDA has launched investigations into the products and now requires manufacturers include warnings about these risks on the products’ labels.

After one FDA safety announcement in 2014, five men sued Abbott Laboratories and its spinoff, AbbVie, Inc., alleging injuries caused by AndroGel. The plaintiffs’ ages range from 50 to 63. Three of the men suffered heart attacks, and two suffered strokes. Scores of lawsuits followed.

Testosterone Risk Studies

Studies published as recently as February 2017 link testosterone products to serious and even deadly side effects, including heart attack, blood clots and stroke.

Heart Attacks
A study published in February 2017 in the Journal of the American Medical Association found an association between testosterone treatment and a significant increase of coronary artery plaque, which can reduce the flow of oxygen to the heart. An earlier study published in 2014 revealed a two-fold increase in the risk of heart attack among men who recently started testosterone therapy.
Blood Clots
Clinical and Applied Thrombosis/Hemostasis published a study in 2013 that found 1.2 percent of men who were hospitalized for deep vein thrombosis or pulmonary embolism had developed the blood clots within three months of starting testosterone therapy.
Strokes
Studies found men who used testosterone products were 30 percent more likely to suffer from strokes. According to a Los Angeles Times report, some of the study participants had to undergo “emergency artery-clearing.

Questionable Marketing

Drug companies that manufacture testosterone replacement drugs like AndroGel heavily market their products promising a better quality of life for men. It’s not uncommon for several television ads to air during football games and shows that target men. Many of these direct-to-consumer ads attributed symptoms associated with aging, such as fatigue and loss of libido, to Low T.

Advertisements for AndroGel, for example, popped up soon after the 2000 FDA approval of the product and became more and more prevalent over time. AbbVie spent $75.6 million on direct-to-consumer marketing for AndroGel in 2012 and $67.9 million in 2013, according to data from market-researcher Kantar Media.

Aggressive marketing tactics such as these have been criticized for allegedly luring otherwise healthy aging men to testosterone. Direct-to-consumer marketing campaigns promote testosterone as a way of regaining youthful levels of energy, sex drive, strength and muscle mass while downplaying potential side effects.

The FDA, however, approved testosterone only to treat specific medical conditions that lead to a drop in testosterone levels in men. But more and more men are using the drugs off-label to treat a wide range of symptoms related to the aging process, such as energy loss, decreased muscle mass and reduced libido.

The New Viagra

Drugmakers often try to increase profits by creating new, unproven uses to piggyback on existing FDA approvals, putting patients at risk by making misleading statements about the drugs’ safety and effectiveness for those unapproved purposes.

It appears makers of testosterone therapies put a new twist on this marketing scheme. Manufacturers like Eli Lilly & Co. and Abbott Laboratories are riding on the successful marketing of Viagra and other erectile dysfunction treatments to encourage men to ask their doctors about testosterone replacement.

Testosterone: ‘The Fountain of Youth’

Websites and TV ads show middle-aged men longing to rejoin sporting activities and ask men if they’ve lost their energy. Direct-to-consumer marketing quizzes set men up to believe that natural signs of aging point to a testosterone deficiency.

However, the FDA warns that “the benefit and safety of these medications have not been established for the treatment of low testosterone levels due to aging, even if a man’s symptoms seem related to low testosterone.” And recent clinical trials found that testosterone did not have an effect on memory or cognitive abilities in older men.

“Low-T” Marketing

Marketing efforts suggest decreased energy levels are caused by Low T rather than by aging or any number of other factors. Once this energy–Low T connection is made, consumers are persuaded to visit their doctors seeking Low T therapy to help them regain vitality.

Eli Lilly & Co., AbbVie and other testosterone product manufacturers face criticism for these and other tactics. They created a $1.6 billion market for testosterone replacement drugs, and critics say they haven’t done enough to inform consumers and doctors about potential risks. Drugmakers have a legal duty to warn consumers and doctors about any known risks associated with their drugs.

Recipe for Pharmaceutical Negligence

While the controversy continues, it’s clear that drugmakers are reaping the rewards of successful marketing of testosterone treatments. But at least one Low-T drugmaker has reportedly come under fire for its marketing practices.

According to a report by McClatchy, a whistleblower lawsuit filed in federal court in Texas alleges that Solvay Pharmaceuticals, formerly Unimed Pharmaceuticals, used improper sales practices to market AndroGel.

The FDA approved AndroGel to treat hypogonadism, but the drugmaker allegedly recruited doctors to help AndroGel “ride (the) coattails of Viagra” by encouraging them to screen patients seeking Viagra for low testosterone. A former sales manager involved in the lawsuit attributes AndroGel’s high sales to the company’s decision to promote the drug for off-label uses even though it isn’t approved to treat erectile dysfunction (ED) like Viagra is.

Details About Unimed Pharmaceuticals:
  • In 1999, it reportedly projected treating a market of 1 million men for hypogonadism.
  • By the time the drug was approved in 2000, it estimated its market at up to 5 million men.
  • By 2003, corporate managers had reportedly expanded that number to 20 million men. (There are an estimated 116 million adult men in the U.S.)
  • Abbott Laboratories is AndroGel’s current owner.
  • Serious health risks and aggressive marketing for off-label purposes frequently form a recipe for negligence and widespread pharmaceutical injuries.
  • Pharmaceutical companies that hurry to market a drug without proper approvals often end up accused of inadequate testing or concealing risks.
  • When they fail to protect consumers and warn about those risks, they may be held legally liable for any injuries that result from their negligence.

Please seek the advice of a medical professional before making health care decisions.

Did you find Drugwatch helpful?

37 Cited Research Articles

  1. U.S. District Court for the Northern District of Illinois. (2015, November 24). Third Amended Master Long-Form Complaint and Jury Demand. Retrieved from https://www.casewatch.org/civil/low_t/third-amended-master-complaint.pdf
  2. Randiellis.com. (n.d.). Randi S. Ellis. Retrieved from http://www.randiellis.com/
  3. Harvard Health Publications. (2015, December 4). Is testosterone therapy safe? Take a breath before you take the plunge. Retrieved from http://www.health.harvard.edu/mens-health/is-testosterone-therapy-safe-take-a-breath-before-you-take-the-plunge
  4. FDA.gov. (2014, January 31). FDA Drug Safety Communication: FDA cautions about using testosterone products for low testosterone due to aging; requires labeling change to inform of possible increased risk of heart attack and stroke with use. Retrieved from https://www.fda.gov/Drugs/DrugSafety/ucm436259.htm
  5. National Library of Medicine. (2013). AndroGel 1 percent. DailyMed. Retrieved from http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c506aaa3-04f8-4eb1-8dc4-e964cdd08e7f
  6. National Library of Medicine. (2013). AndroGel 1.62 percent. DailyMed. Retrieved from http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8677ba5b-8374-46cb-854c-403972e9ddf3
  7. Finkle, W.D., Greenland, S., Ridgeway, G.K., Adams, J.L., Frasco, M.A., Cook, M.B., Fraumeni, Jr., J.F. & Hoover, R.N. (2014). Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men. PLoS One. Retrieved from http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0085805
  8. Healy, M. (2014, January 29). Testosterone prescriptions linked to heart attack. L.A. Times. Retrieved from http://www.latimes.com/science/sciencenow/la-sci-sn-testosterone-heart-attack-20140129-story.html
  9. Sundar, S. (2014, September 12). Pfizer's testosterone drug poses heart risks, suit says. Law 360. Retrieved from http://www.law360.com/articles/576790/pfizer-s-testosterone-drug-poses-heart-risks-suit-says
  10. U.S. National Library of Medicine. (2014). DEPO-TESTOSTERONE- testosterone cypionate injection, solution. DailyMed. Retrieved from http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cfbb53d4-b868-4a28-8436-f9112eb01c39&
  11. Vigen, R., O'Donnell C.I., Baron, A.E., Grunwald, G.K., Maddox, T. M., Bradley, S. M., …& Ho, Ho, P.M. (2013). Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA. Retrieved from http://jama.jamanetwork.com/article.aspx?articleID=1764051
  12. Rabin, R. C. (2014, February 3). Weighing testosterone's benefits and risks. New York Times. Retrieved from http://well.blogs.nytimes.com/2014/02/03/weighing-testosterone-benefits-and-risks/?_php=true&_type=blogs&_r=0
  13. Solvay Pharmaceuticals, Inc. (2009). AndroGel 1% CIII Briefing Book. Retrieved from http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/PediatricAdvisoryCommittee/UCM166950.pdf
  14. Rosenthal, E. (2013, October 15). A push to sell testosterone gels troubles doctors. New York Times. Retrieved from http://www.nytimes.com/
  15. Monthly Prescribing Reference (2011, May 2). AndroGel 1.62% Approved for Hypogonadism. Retrieved from http://www.empr.com/androgel-162-approved-for-hypogonadism/article/201947/
  16. U.S. Securities and Exchange Commission. (2017, November 9). Form 10-Q Quarterly Report. Endo International PLC. Retrieved http://investor.endo.com/node/13931/html
  17. U.S. Securities and Exchange Commission. (2016, December 31). Form 10-K. Annual Repoort. Endo International PLC. Retrieved http://investor.endo.com/static-files/4088f2e1-9110-4227-8dd9-2d1d528d7edc
  18. Endo International plc. (2015, January 29). Endo Completes Acquisition of Auxilium Pharmaceuticals. PR Newswire. Retrieved https://www.prnewswire.com/news-releases/endo-completes-acquisition-of-auxilium-pharmaceuticals-300028144.html
  19. GSK. (2012, May 21). Auxilium Pharmaceuticals, Inc. and GlaxoSmithKline LLC enter into a co-promotion agreement for Testim in the U.S. Retrieved https://us.gsk.com/en-us/media/press-releases/2012/auxilium-pharmaceuticals-inc-and-glaxosmithkline-llc-enter-into-a-co-promotion-agreement-for-testim-in-the-us/
  20. U.S. Securities and Exchange Commission. (2018, February 20). Form 10-K Annual Report. Eli Lilly. Retrieved https://investor.lilly.com/secfiling.cfm?filingID=59478-18-89&CIK=59478
  21. U.S. District Court for the Northern District of Illinois. (2018, February 6). In Re: Testosterone Replacement Therapy Products Liability Litigation. Notification of Docket Entry. Retrieved from http://www.pacer.gov
  22. U.S. District Court for the Northern District of Illinois. (2018, February 23). In Re: Testosterone Replacement Therapy Products Liability Litigation. Case Management Order 98. (stay of Endo, Auxilium & GSK cases). Retrieved from http://www.pacer.gov
  23. U.S. District Court for the Northern District of Illinois. (2018, February 24). In Re: Testosterone Replacement Therapy Products Liability Litigation. Case Management Order 99. (Scope of new trial in Mitchell v. AbbVie.). Retrieved from http://www.pacer.gov
  24. U.S. District Court for the Northern District of Illinois. (n.d.). MDL 2545. Member Cases. Retrieved from http://www.ilnd.uscourts.gov/mdl-details.aspx?UGlDS1bLxpRHyfdf3l5DJQ==#collapse_2545_5
  25. Feeley J. et al. (2018, February 23). Endo, Glaxo to Settle Suits over Testosterone-Replacement Drugs. Retrieved https://www.bloomberg.com/news/articles/2018-02-23/endo-glaxo-to-settle-suits-over-testosterone-replacement-drugs
  26. Bellon, T. (2018, January 19). 7th Circuit upholds dismissal of testosterone replacement MDL cases. Retrieved https://www.reuters.com/article/products-testosterone/7th-circuit-upholds-dismissal-of-testosterone-replacement-mdl-cases-idUSL1N1PF00V
  27. U.S. District Court for the Northern District of Illinois. (2018, January 19). Rodney Guilbeau et al., v. Pfizer Inc. and Pharmacia & Upjohn Company LLC. MDL No. 2545 Master Docket Case No. 1:14-cv-1748. Retrieved http://media.ca7.uscourts.gov/cgi-bin/rssExec.pl?Submit=Display&Path=Y2018/D01-19/C:17-2056:J:Hamilton:aut:T:fnOp:N:2093761:S:0
  28. U.S. Judicial Panel on Multidistrict Litigation. (2018, May 15). MDL Statistics Report. Retrieved from http://www.jpml.uscourts.gov/sites/jpml/files/Pending_MDL_Dockets_By_District-May-15-2018.pdf
  29. United States Judicial Panel on Multidistrict Litigation. (2018, May 15). MDL Statistics Report- Distribution of Pending MDL Dockets by Actions Pending. Retrieved http://www.jpml.uscourts.gov/sites/jpml/files/Pending_MDL_Dockets_By_Actions_Pending-May-15-2018.pdf
  30. Field, E. (2018, May 16). Ill. Jury Finds For AbbVie In AndroGel Bellwether Trial. Retrieved https://www.law360.com/lifesciences/articles/1044500/ill-jury-finds-for-abbvie-in-androgel-bellwether-trial
  31. U.S. District Court for the Northern District of Illinois. (2018, March 26). Judgment in A Civil Case. Jesse Mitchell v. AbbVie Inc. and Abbott Laboratories. Case: 1:14-cv-09178. Retrieved http://www.pacer.gov
  32. Sagonowsky, E. (2018, June 12). After Setting Aside $200M, Endo Settles 1,300 Testosterone Liability Lawsuits. FiercePharma. Retrieved from https://www.fiercepharma.com/pharma/after-setting-aside-200m-endo-settles-1-300-testosterone-liability-lawsuits
  33. AbbVie. (2018, March 31). Quarterly Report filed with United States Securities and Exchange Commission. Form 110-Q). Retrieved http://investors.abbvie.com/node/11691/html
  34. U.S. District Court for the Northern District of Illinois. (2015, March 30). Testosterone Replacement Therapy Products Liability Litigation. MDL No. 2545. Case No. 1:14cv-01748. Master Short Form Complaint for Robert and Sherrie Rowley. Retrieved from http://www.pacer.gov
  35. U.S. District Court for the Northern District of Illinois. (2018, April 19). Testosterone Replacement Therapy Products Liability Litigation. MDL No. 2545. Case No. 1:14cv-01748. Case Management Order 114. Retrieved from http://www.pacer.gov
  36. U.S. District Court for the Northern District of Illinois. (2018, June 13). Testosterone Replacement Therapy Products Liability Litigation. Case 1:14-cv-1085 Document # 69. Plaintiff’s Rule 59 Motion for a New Trial. Retrieved http://www.pacer.gov
  37. Jones, D.N. (2018, June 14). AbbVie Wind 5th Bellwether in Testosterone MDL. Retrieved https://www.law360.com/classaction/articles/1053802
View All Sources
Who Am I Calling?

Calling this number connects you with Wilson and Peterson, LLP or one of its trusted legal partners. A law firm representative will review your case for free.

Wilson and Peterson, LLP funds Drugwatch because it supports the organization’s mission to keep people safe from dangerous drugs and medical devices.

(844) 277-7079

To contact Drugwatch Managing Editor Kevin Connolly, call (855) 839-9780.

Live Chat Icon livechat loading spinner